Oklo or Palantir: Cathie Wood Buys $4.1M of One Stock, Sells $5.3M of the Other
I'm LongbridgeAI, I can summarize articles.ARK Invest founder Cathie Wood purchased $4.1 million worth of Oklo shares while selling $5.3 million of Palantir stock. This move reflects a bet on Oklo's nuclear technology recovery despite its 62% year-to-date decline and high development costs, against trimming exposure to Palantir following its 54% rally driven by AI demand.
Closely followed investor and ARK Invest founder Cathie Wood is making some moves involving two stocks that have taken opposite paths this year. Oklo (NYSE:OKLO), the nuclear technology developer backed by Sam Altman, has tumbled 62% year-to-date, leaving investors wondering whether its long-term potential can justify the risks. With commercial operations still years away, patience is becoming harder to maintain as development costs continue to mount.
Meanwhile, Palantir (NASDAQ:PLTR) has been rewarding investors over the past two and a half months, climbing 54% since its early August earnings report. The software giant has benefited from soaring demand for AI solutions, particularly among government agencies and large corporations. Yet, its rapid ascent has raised concerns, as the market weighs the company's strong growth against an expensive valuation.
Cathie Wood appears willing to bet on a recovery in Oklo while trimming her exposure to Palantir. On Tuesday, her ARK funds purchased 150,998 OKLO shares worth about $4.1 million. At the same time, Wood sold 27,790 PLTR shares valued at $5.3 million, taking some money off the table following the software specialist's extended rally.
Oklo's Nuclear Promise Faces a Costly Reality
Oklo's biggest problem is that its commercial plans remain far ahead of actual revenue generation. The company wants to supply reliable nuclear electricity to data centers through its Aurora reactors, capitalizing on the growing energy needs of AI infrastructure. However, regulatory hurdles, construction timelines, and the costs of bringing advanced reactors into operation have made investors less willing to pay a premium for future potential.
Financing concerns have added to the selling, particularly as Oklo continues raising capital before commercial electricity sales begin. The company secured billions through equity offerings earlier this year and introduced another $1 billion stock-sale program in September. Although these transactions provide financial flexibility, they also raise dilution concerns among existing investors. Oklo has also projected operating cash expenditures of $120 million to $150 million for 2026, reinforcing worries about how much additional funding its expansion plans could require.
Still, the nuclear developer continues making progress toward its long-term goals, despite the punishment its stock has received. Earlier this month, Oklo announced plans for its Groves-2 Forge isotope facility under a Department of Energy initiative, targeting materials used in cancer treatments. Its Aurora project in Idaho has also secured preliminary safety approval, bringing the company another step closer to commercial deployment.
Wall Street remains divided over Oklo's prospects, with 7 Buys and 6 Holds giving the stock a Moderate Buy consensus rating. Yet, analysts see the potential for a strong recovery; the average 12-month price target of $70.72 suggests a 157% upside from current levels. (See OKLO stock forecast)